D. Lesuisse

发表

1.2 Importance of Chirality in the Field of Anti-infective Agents

D. Lesuisse, M. Tabart, 2012 .

Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.

C. Venot, H. Strobel, D. Lesuisse, 2011, Bioorganic & medicinal chemistry letters.

Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

E. Mandine, G. Lange, P. Broto, 2003, Journal of medicinal chemistry.

Non-Human Primate Blood–Brain Barrier and In Vitro Brain Endothelium: From Transcriptome to the Establishment of a New Model

G. Thill, D. Lesuisse, Catarina Chaves, 2020, Pharmaceutics.

Src homology‐2 domain binding assays by scintillation proximity and surface plasmon resonance

E. Mandine, D. Lesuisse, P. Deprez, 2001, Journal of molecular recognition : JMR.

Harnessing C-H Activation of Benzhydroxamates as a Macrocyclization Strategy: Synthesis of Structurally Diverse Macrocyclic Isoquinolones.

C. Meyer, J. Cossy, D. Lesuisse, 2016, Chemistry.

Search and Characterization of ITM2A as a New Potential Target for Brain Delivery

A. Frenzel, J. Guillemot, P. Kuhn, 2021 .

SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2.

Jean-Pierre Marquette, E. Mandine, G. Lange, 2002, Journal of medicinal chemistry.

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

S. Summerfield, C. Bundgaard, G. Terstappen, 2022, Pharmaceutical Research.

Biphenyls as surrogates of the steroidal backbone. Part 1: synthesis and estrogen receptor affinity of an original series of polysubstituted biphenyls.

G. Teutsch, D. Lesuisse, E. Albert, 2001, Bioorganic & medicinal chemistry letters.

Design of Potent IGF1‐R Inhibitors Related to Bis‐azaindoles

C. Venot, W. Metz, F. Ding, 2010, Chemical biology & drug design.

Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.

M. Castel, P. Barnéoud, T. Rooney, 2019, Bioorganic & medicinal chemistry letters.

An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family

B. Cameron, D. Lesuisse, Catarina Chaves, 2022, PloS one.

Peptidomics of Haemonchus contortus

A. Maule, V. Mikol, J. Guillemot, 2021, ACS omega.

Exploring ITM2A as a new potential target for brain delivery

A. Frenzel, J. Guillemot, P. Kuhn, 2022, Fluids and Barriers of the CNS.

Biphenyls as surrogates of the steroidal backbone. Part 2: discovery of a novel family of non-steroidal 5-alpha-reductase inhibitors.

G. Teutsch, D. Lesuisse, E. Albert, 2001, Bioorganic & Medicinal Chemistry Letters.

Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding.

T. T. Duc, E. Mandine, G. Lange, 2001, Bioorganic & medicinal chemistry letters.

Synthetic applications of N-acylamino-1,3-dienes. 10. Importance of allylic interactions and stereoelectronic effects in dictating the steric course of the reaction of iminium ions with nucleophiles. An efficient total synthesis of (.+-.)-gephyrotoxin

L. Overman, D. Lesuisse, M. Hashimoto, 1983 .

Rhodium(III)-Catalyzed C-H Activation/Heterocyclization as a Macrocyclization Strategy. Synthesis of Macrocyclic Pyridones.

C. Meyer, J. Cossy, D. Lesuisse, 2017, Organic letters.

A new route to 19-substituted steroids from 19-nor steroids: Sigmatropic [3,3] and [2,3] rearrangements revisited

D. Lesuisse, B. Tric, F. Canu, 1994 .

Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.

E. Mandine, G. Lange, B. Schoot, 2002, Bioorganic & medicinal chemistry letters.

Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding.

T. T. Duc, E. Mandine, G. Lange, 2001, Bioorganic & medicinal chemistry letters.

The synthesis of indolizidines by intramolecular ene cyclizations. Preparation of (E)-alkylidene analogs of pumiliotoxin A.

L. Overman, D. Lesuisse, 1985 .

Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease

P. Barnéoud, D. Lesuisse, X. Vigé, 2019, Data in brief.

2-Amino-1-azetines, a new class of strained amidines

D. Lesuisse, L. Ghosez, J. Marchand‐Brynaert, 1980 .

The Synthesis of Indolizidines by Intramolecular Ene Cyclizations.

L. Overman, D. Lesuisse, 1986 .

Efficient and modular synthesis of new structurally diverse functionalized [n]paracyclophanes by a ring-distortion strategy.

C. Meyer, J. Cossy, D. Lesuisse, 2014, Angewandte Chemie.

Chapter 30 – Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties

C. Wermuth, D. Lesuisse, 2015 .

(-)-Methyl 4,5-O-benzylidene-4-epi-shikimate: an intermediate for the synthesis of (-)-chorismic acid and analogs

G. A. Berchtold, D. Lesuisse, 1985 .

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

D. Lesuisse, P. Lafaye, Elodie Pothin, 2020, Pharmaceutics.

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.

R. Baron, R. Rickles, S. Violette, 2001, Bone.

RU54115, a tight-binding aromatase inhibitor potentially useful for the treatment of breast cancer

D. Lesuisse, B. Tric, J. Gourvest, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[New formats for improving brain drug delivery of antibodies: the blood-brain barrier case].

X. Declèves, D. Lesuisse, P. Lafaye, 2019, Medecine sciences : M/S.

Determination of oenothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum.

G. Teutsch, M. Lowinski, P. Devaux, 1996, Journal of natural products.

Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein.

E. Mandine, Eliane Mandine, D. Lesuisse, 2002, Bioorganic & medicinal chemistry letters.

Imidazole-based ligands of the Src SH2 protein.

E. Mandine, D. Lesuisse, P. Deprez, 2002, Bioorganic & medicinal chemistry letters.

The Therapist's Interventions in Jungian Analysis

D. Lesuisse, M. Leysen, R. Schols, 2012 .

Overview: Recent Developments in Aromatase Inhibition

D. Lesuisse, 1993 .

Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model

Nicolas Moindrot, D. Boulay, O. Bergis, 2020, Molecular therapy. Methods & clinical development.

Novel biphenyl compounds, process and preparation intermediates, medicament application and pharmaceutical compositions comprising the same

D. Lesuisse, 1996 .

Biphenyls as Surrogates of the Steroidal Backbone. Part 2. Discovery of a Novel Family of Non‐steroidal 5‐α‐Reductase Inhibitors.

G. Teutsch, D. Lesuisse, E. Albert, 2001 .

Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.

M. Dreyer, T. Rooney, D. Lesuisse, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.

D. Lesuisse, D. Philibert, C. Hartmann, 1992, Journal of medicinal chemistry.

Design of Potent IGF1‐R Inhibitors Related to Bis‐azaindoles

C. Venot, F. Ding, D. Lesuisse, 2010, Chemical biology & drug design.

Harnessing C-H Activation of Benzhydroxamates as a Macrocyclization Strategy: Synthesis of Structurally Diverse Macrocyclic Isoquinolones.

C. Meyer, J. Cossy, D. Lesuisse, 2016, Chemistry.